With Disclosure of Recently Met Benchmarks for Its Adult Tissue Stem Cell Counting Technology, Asymmetrex Targets Applications to Enable Gene-Editing Therapies Yesterday, tissue stem cell biotechnology start-up company Asymmetrex, LLC posted results on its website from the most recently completed benchmark studies for its computer simulation technology for determining the number of stem cells in
Asymmetrex Launches a Crowdsourcing Campaign to Introduce New Biomarkers for Counting Previously Elusive Tissue Stem Cells To go directly to the Asymmetrex crowd description page, click here. Stem cell medicine technology start-up company Asymmetrex, LLC faces the unusual challenge of wishing to evaluate its new biomarker technologies, developed to count tissue stem cells for the
Asymmetrex Interviewed in Anticipation of Presentations at the 14th Annual World Preclinical Congress Focused on Tackling Translation Challenges In a recent interview, Asymmetrex, LLC founder and director James L. Sherley, M.D., Ph.D. talks about the company’s upcoming participation in forums to address “3D Models for Toxicological Research” at the 14th Annual World Preclinical Congress, scheduled
At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells Although pharmaceutical companies recognize that promising new drugs that are toxic to adult stem cells are likely to fail, the industry has been unable to do much about this problem, which is estimated to
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult Stem Cell Medicine at U.S. and U.K. Conferences Already in 2015, the adult stem cell technology company Asymmetrex is scheduled to present at both industry and academic conferences in the U.S. and the U.K. The company will share
10/30/2014 Boston, MA (PRWEB) For Immediate Release- James Sherley says he has been working towards Asymmetrex’s new advance in adult tissue stem cell technology since his days as a principal investigator at the Fox Chase Cancer Center (FCCC) in Philadelphia in the late 1990’s. Sherley founded Asymmetrex as a new Boston biotech start-up last year. The
For immediate release. Boston, Massachusetts (PRWEB) September 25, 2014 The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America International Partnering Conference in Boston, MA A year after its formation in September 2013, Boston’s Adult Stem Cell Technology Center, LLC (ASCTC) was invited to present its commercialization plans and